2. Metabolic Enzyme/Protease
  3. Ceramidase Acyltransferase
  4. Fumonisin B2

Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma.

For research use only. We do not sell to patients.

Fumonisin B2

Fumonisin B2 Chemical Structure

CAS No. : 116355-84-1

Size Price Stock Quantity
500 μg In-stock
1 mg In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Fumonisin B2:

Fumonisin B2 Related Antibodies

Top Publications Citing Use of Products

View All Acyltransferase Isoform Specific Products:

View All Isoforms
ACAT1 ACAT2 MGAT2 ACAT DGAT1 DGAT2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma[1][2][3].

IC50 & Target

Sphingosine N-acyltransferase[2]
In Vitro

Fumonisin B2 (10-35 μM; 3-5 days) exerts a proliferation-inhibiting effect on LLC-PK1 cells; the cells first exhibit fibroblast-like morphological changes, and this effect is reversible after drug removal[1].
Fumonisin B2 (5 μM; 1 h) binds to lactic acid bacteria (e.g., Lactobacillus paraplantarum CNRZ 1885, Streptococcus thermophilus RAR1) under acidic conditions, with a stronger binding capacity than Fumonisin B1[2].
Fumonisin B2 (7 days of culture; 50 minutes of extraction) is exclusively produced by Aspergillus niger strains NRRL 3122, NRRL 328, NRRL 3 and NRRL 326, with the highest yield observed on Czapek yeast autolysate agar supplemented with 5% NaCl, and no toxin production is detected on malt extract agar[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fumonisin B2 Related Antibodies
In Vivo

Fumonisin B2 (0.75 mg/kg; i.p.; once daily; 2, 4, 6 days) reduces body weight and food consumption, increases serum levels of cholesterol, alanine aminotransferase (ALT), creatinine, total protein, IgM, calcium and magnesium, elevates the number of vacuolated cells in bone marrow, induces single-cell necrosis in the liver and kidney, cytoplasmic vacuolization in the adrenal cortex, and thymic lymphocyte lysis in male Sprague-Dawley rats. It also upregulates the mRNA expression of p21 and cyclin E genes, and downregulates the mRNA expression of p27 and cyclin D1 genes in the liver. No significant changes are observed in the hepatic protein levels of p27 and cyclin E, while the protein levels of cyclin D1 and PCNA remain unaffected[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 42-48-day-old male Sprague-Dawley rats ( 149.1±0.8 g to 181.9±1.3 g)[4]
Dosage: 0.75 mg/kg
Administration: Intraperitoneal injection; once daily; for 2, 4, or 6 days.
Result: Showed a significant decrease in body weight only on the last 2 days of the 6-day study.
Significantly reduced the food consumption on the second to last day of the 4-day study and the last 2 days of the 6-day study.
Significantly elevated the serum biochemical parameters including alanine aminotransferase (ALT), creatinine, total protein, IgM, calcium, and magnesium on day 6.
Increased the number of vacuolated bone marrow cells consistently at all time points.
Resulted histopathological changes included single cell necrosis in the liver and kidneys, cytoplasmic vacuolation in the adrenal cortex, and mild to moderate lymphocytolysis in the thymic cortex after 4 and 6 days of exposure.
In the liver, significantly upregulated mRNA expression of p21 and cyclin E genes, while significantly downregulated mRNA expression of p27 and cyclin D1 genes.
There were no significant changes in the protein levels of p27, cyclin E, cyclin D1, and proliferating cell nuclear antigen (PCNA) compared to the control group.
Molecular Weight

705.83

Formula

C34H59NO14
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

OC(C[C@@H](C(O)=O)CC(O[C@@H](C[C@@H](C)CCCCCC[C@@H](O)C[C@H](O)[C@@H](N)C)[C@@H]([C@H](C)CCCC)OC(C[C@H](C(O)=O)CC(O)=O)=O)=O)=O
Structure Classification
Initial Source

Aspergillus niger
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Purity & Documentation

Purity: 99.99%

SDS (419 KB)

COA (249 KB) HNMR (247 KB) RP-HPLC (261 KB) MS (130 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Fumonisin B2 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fumonisin B2116355-84-1Fumonisin B 2Fumonisin B-2CeramidaseAcyltransferaseDiacylglycerol acyltransferaseDiglyceride acyltransferaseacyl-CoA:cholesterol acyltransferasemono- acylglycerol acyltransferaseAspergillus nigerGibberella fujikuroi species complexesophageal cancermalt extract agarFusarium verticillioidesNRRL 3122NRRL 328MRC 826Czapek yeast autolysate agarFusarium oxysporum species complexInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Fumonisin B2
Cat. No.:
HY-N6723
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB) Italian - IT (419 KB) Korean - KR (419 KB) Portuguese - PT (419 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.